<p>A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of <em>C. difficile</em> infection recurrence up to 8 weeks after treatment. </p>

A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.

Could SER-109 be an Answer for Recurrent C.Difficile Infection?

We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.

Share Could SER-109 be an Answer for Recurrent C.Difficile Infection?

Sign up to save your podcasts

Could SER-109 be an Answer for Recurrent C.Difficile Infection?

Could SER-109 be an Answer for Recurrent C.Difficile Infection?